NASDAQ$SKIN
SkinHealth Systems Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported record fourth quarter and fiscal year 2021 financial results.
The Beauty Health Company reported strong Q4 2021 results with net sales increasing 105.6% compared to Q4 2020, driven by growth in the U.S., EMEA, and APAC regions. The company exceeded its guidance for the quarter and full year, navigating macro challenges and COVID-19 impacts.
- Net sales increased 105.6% compared to Q4 2020, reaching $77.9 million.
- Delivery Systems net sales increased to $42.7 million, with over 1,800 systems sold during the quarter.
- Consumables net sales increased to $35.2 million compared to the same period last year.
- Adjusted EBITDA increased to $8.5 million compared to $3.6 million in Q4 2020.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$77.9M
Revenue by segment
Beauty Health · $77.9M total across 2 segments · Q4 2021
- Delivery Systems$42.7M+145.4%54.8%
- Consumables$35.2M+71.7%45.2%
Forward guidance
BeautyHealth is providing a fiscal 2022 net sales guidance range of $320.0 million to $330.0 million and adjusted EBITDA of approximately $50.0 million.
Tailwinds
- Momentum in health and wellness
- Management's confidence in the business as the Company executes against its growth plan
- Launch in the first half of 2022 of Syndeo, the next generation HydraFacial Delivery System
- Wi-Fi-enabled radio frequency identification that will allow us to build a connected platform
- Better understand consumer and provider behavior
Headwinds
- No material deterioration in general market conditions or other factors related to COVID-19 trends
- Potential risk for further market closures or other restrictive measures from existing or new COVID-19 strains
- Uneven global rollout and adoption of vaccines
- Inflationary headwinds related to higher raw material, shipping and labor costs
- Assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures persist or are reimplemented
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro